EP 4217385 A2 20230802 - ANTIBODIES AGAINST SARS-COV-2
Title (en)
ANTIBODIES AGAINST SARS-COV-2
Title (de)
ANTIKÖRPER GEGEN SARS-COV-2
Title (fr)
ANTICORPS CONTRE LE SARS-COV-2
Publication
Application
Priority
- US 202063084501 P 20200928
- US 202063111435 P 20201109
- US 202063112505 P 20201111
- US 202063119545 P 20201130
- US 202163137112 P 20210113
- US 202163170356 P 20210402
- US 2021052481 W 20210928
Abstract (en)
[origin: WO2022067269A2] The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, an antibody or antigen-binding fragment is capable of binding to a SARS-CoV-2 spike protein in the N-terminal domain (NTD). Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise a polynucleotide, host cells that express an antibody or antigen-binding fragment, pharmaceutical compositions, and methods for treating or diagnosing a SARS-CoV-2 infection.
IPC 8 full level
C07K 16/10 (2006.01); A61P 31/14 (2006.01)
CPC (source: EP US)
A61P 31/14 (2018.01 - EP US); C07K 16/1003 (2023.08 - EP US); A61K 2039/505 (2013.01 - EP); A61K 2039/507 (2013.01 - EP); A61K 2039/545 (2013.01 - EP); C07K 2317/21 (2013.01 - EP); C07K 2317/526 (2013.01 - EP); C07K 2317/71 (2013.01 - EP); C07K 2317/76 (2013.01 - EP); C07K 2317/92 (2013.01 - EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022067269 A2 20220331; WO 2022067269 A3 20220623; BR 112023005684 A2 20231107; CA 3194162 A1 20220331; EP 4217385 A2 20230802; JP 2023545322 A 20231027
DOCDB simple family (application)
US 2021052481 W 20210928; BR 112023005684 A 20210928; CA 3194162 A 20210928; EP 21806447 A 20210928; JP 2023544186 A 20210928